Amicus Therapeutics, Inc.FOLD

Amicus Therapeutics is a biotechnology company focused on developing and commercializing therapies for rare and orphan diseases, with its primary revenue derived from treatments for Pompe disease and other lysosomal storage disorders. The company operates in the niche rare disease market, where competition is limited but regulatory and commercial hurdles are high. With trailing twelve-month revenue of $634.21 million, Amicus fits within the mid-cap biotech tier, though it remains unprofitable on a net income basis. Its defining characteristic is a targeted rare-disease pipeline that provides a degree of product exclusivity, but profitability has proven elusive due to ongoing research and development costs.